Abstract: Chimeric antigen receptor-modified lymphocyte is a type of cancer immunotherapies. By re-engineering antigen receptor in vitro, it can be expressed on the membrane of lymphocytes and increase the function of killing cancer cells. It is now the most attractive field of cancer immunotherapies in hematologic malignancies, especially in B-cell malignancies by its significant therapeutic effect. Multiple myeloma (MM) is the second common hematologic cancer in the elderly populations. Up to now, it is still incurable. Researchers have been exploring the applications of immunotherapy in MM. This review discusses the recent development of chimeric antigen receptor-modified lymphocytic cell technology and its application in multiple myeloma.